Compare Amphastar Pharmaceuticals Inc (AMPH) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Intuitive Surgical, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.55 (market cap $826.08M), while Intuitive Surgical, Inc. trades at $413.56 (market cap $144.07B). The key difference: Intuitive Surgical, Inc. is far larger — about 174.4× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| AMPH | ISRG | |
|---|---|---|
Market Cap | $826.08M | $144.07B |
Sector | Health | Health |
52-Week High | $30.81 | $592.85 |
52-Week Low | $16.87 | $397.68 |
Enterprise Value | $1.22B | $139.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Intuitive Surgical (ISRG) trades at $406.78, down 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings of $2.50 EPS, beating estimates, with revenue reaching $10.06 billion in 2025 and net income margin at 28.15%. Analyst consensus is bullish with a $556.10 price target, though valuation ratios like P/E of 49.43 remain elevated. Recent news highlights Q2 2026 earnings anticipation on July 16 and ongoing adoption of da Vinci 5 systems.
Outlook is positive due to consistent earnings beats and robust revenue growth, but risks include high valuation sensitivity and competitive pressures. The stock offers long-term growth potential in robotic surgery, yet investors should monitor margin trends and quarterly results for sustained momentum amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
